Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by MaaT Pharma

< Previous 1 2 3 Next >
News headline image
MaaT Pharma to Present Four Abstracts at the 52nd European Bone Marrow Transplantation Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD Management
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma Presents Updated Preclinical Data at SITC Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma Reports Financial Results for the Third Quarter 2025 and Provides Financing Update
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma Announces Positive Phase 3 Results Evaluating Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease Selected for Oral Presentation at ASH Congress 2025
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma Publishes Its Half Year 2025 Results and Provides a Business Update
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease in Europe
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Congress Validating High Efficacy Observed in Pivotal ARES Study in Acute Graft-versus-Host Disease
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma Announces Initiation of Coverage of its Stock by H.C. Wainwright & Co
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024 Annual Results
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial Evaluating MaaT013 in Acute Graft-versus-Host Disease
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease
From MaaT Pharma
Via Business Wire
News headline image
CORRECTING and REPLACING: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease
From MaaT Pharma
Via Business Wire
News headline image
MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
From MaaT Pharma
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.